Verishibo-B (09887): Summary of the Phase II clinical study of Vilisin™ (opatisumimab, PD-L1/4-1BB bispecific antibody, LBL-024) first-line treatment of NSCLC published on the WCLC website

According to Zhitong Finance App News, Weilizhibo-B (09887) announced that the full text of the Phase II clinical study summary of the first-line treatment of non-small cell lung cancer (NSCLC) with the drug Velisin™ (opatisumimab, PD L1/4-1BB bispecific antibody), developed independently by the company, has been officially released on the official website of the World Lung Cancer Conference (WCLC). Based on data analysis as of March 6, 2026, Verisin™ chemotherapy showed encouraging objective remission rates (ORR) in the overall population, while strong tumor shrinkage effects were observed in both squamous cell carcinoma and non-squamous cell carcinoma subgroups. The data disclosed in the abstract is based on a follow-up of only 3.6 months, and the latest data with a follow-up period of more than seven months will be announced during the WCLC oral presentation on September 14, 2026.

According to summary data, first-line treatment of locally advanced or metastatic NSCLC with Verisin™ chemotherapy reached 65.0%, ORR reached 65.0% and disease control rate (DCR) reached 95.0% in 60 patients whose efficacy could be assessed. In the squamous cell carcinoma subgroup, the ORR was 77.4% and the DCR was 96.8%, while the ORR in the non-squamous cell carcinoma subgroup was 51.7% and the DCR was 93.1%. Overall safety was manageable, and no new safety signals were observed.

The data disclosed in the abstract was followed for 3.6 months at the time of initial submission. The previous findings will be further verified by WCLC's on-site follow-up data for more than seven months. As follow-up time is extended, data continues to mature, the depth of response continues to deepen, and the trend of benefiting from progression-free survival (PFS) continues to increase. Together, the above results support Velisign™'s unique “break the brake and step on the throttle” dual-target immune coordination mechanism, which is expected to establish a new IO 2.0 treatment path for NSCLC. Currently, Velisin™ is undergoing 11 clinical studies and has shown clear and positive efficacy signals in multiple indications. Clinical data for the top 7 indications all showed potential best-in-class (BIC) treatment prospects.